Home > Insider Trading > Filing (0001140361-16-089278)

Filing Details

Accession Number:: 0001140361-16-089278
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-12-09 16:51:21
Reporting Period:: 2016-12-07

Filing Date:: 2016-12-09
Accepted Time:: 2016-12-09 16:51:21
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1445283	Proteostasis Therapeutics Inc.	PTI	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1583977	Cormorant Asset Management, Llc	200 Clarendon Street, 52Nd Floor Boston MA 02116	No	No	Yes	No
1599214	Bihua Chen	C/O Cormorant Asset Management, Llc 200 Clarendon Street, 52Nd Floor Boston MA 02116	Yes	No	Yes	No
1618442	Cormorant Global Healthcare Master Fund, Lp	200 Clarendon Street, 52Nd Floor Boston MA 02116	No	No	Yes	No
1618451	Cormorant Global Healthcare Gp, Llc	200 Clarendon Street, 52Nd Floor Boston MA 02116	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-12-07	22,598	$10.74	3,660,907	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2016-12-08	21,819	$10.93	3,682,726	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Footnotes

Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and by a managed account (the "Account"). Cormorant Asset Management, LLC ("Cormorant") serves as the investment manager of the Master Fund and the Account. Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant and GP LLC. GP LLC may be deemed to beneficially own the shares held by the Master Fund, and Cormorant and Ms. Chen may be deemed to beneficially own the shares held by the Master Fund and the Account.
Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
Represents the weighted average purchase price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $10.50 to $10.75 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. Of these shares, 18,790 were purchased for the Master Fund and 3,808 shares were purchased for the Account. As of December 7, 2016, the Master Fund held 3,044,422 shares, and the Account held 616,485 shares.
Represents the weighted average purchase price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $10.67 to $11.00 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. Of these shares, 18,142 were purchased for the Master Fund and 3,677 shares were purchased for the Account. As of December 8, 2016, the Master Fund held 3,062,564 shares, and the Account held 620,162 shares.